Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia

Academic Article

Abstract

  • © 2015 Informa UK, Ltd. With the growing complexity of treatment options for chronic lymphocytic leukemia (CLL) and variables that influence the underlying biology of this disease, providing allogeneic stem cell transplant (alloSCT) to appropriate candidates poses a challenge for transplant physicians. Novel small molecule inhibitors hold unprecedented promise for poor-risk subgroups, which will likely alter decision-making and referral patterns for transplant. In this review, we analyze what is known and may still remain true about indications for transplant based on outcomes reported in the literature recently and over the last decade.
  • Digital Object Identifier (doi)

    Author List

  • Innis-Shelton RD; Davis RS; Lamb L; Mineishi S
  • Start Page

  • 1626
  • End Page

  • 1635
  • Volume

  • 56
  • Issue

  • 6